Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has been assigned an average rating of “Hold” from the twenty-five brokerages that are covering the stock, MarketBeat reports. Five equities research analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $127.06.
Several analysts have recently weighed in on ICPT shares. Cantor Fitzgerald upgraded Intercept Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $69.00 price target on the stock in a report on Wednesday, November 1st. Deutsche Bank started coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They set a “buy” rating and a $106.00 price target on the stock. Credit Suisse Group set a $167.00 price target on Intercept Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, January 22nd. BidaskClub cut Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 16th. Finally, Wedbush restated a “buy” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a report on Friday, January 5th.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at $53.29 on Friday. The firm has a market capitalization of $1,457.93, a PE ratio of -3.60 and a beta of -2.13. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. Intercept Pharmaceuticals has a twelve month low of $51.53 and a twelve month high of $135.59.
ILLEGAL ACTIVITY NOTICE: “Intercept Pharmaceuticals Inc (ICPT) Receives Consensus Rating of “Hold” from Analysts” was first published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/09/intercept-pharmaceuticals-inc-icpt-receives-consensus-rating-of-hold-from-analysts.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.